182 studies found for:    "Scleroderma, Systemic"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting IL1-TRAP, Rilonacept, in Systemic Sclerosis
Conditions: Scleroderma;   Systemic Sclerosis;   Diffuse Scleroderma;   Diffuse Systemic Sclerosis
Interventions: Drug: Rilonacept;   Drug: Placebo
2 Unknown  Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis
Conditions: Scleroderma, Systemic;   Scleroderma, Diffuse;   Scleroderma, Limited;   Raynaud Phenomenon
Interventions: Drug: Sildenafil citrate;   Drug: Placebo
3 Recruiting Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
Conditions: Scleroderma, Systemic;   Sclerosis, Systemic;   Systemic Scleroderma;   Systemic Sclerosis
Interventions: Drug: Pomalidomide (CC-4047);   Drug: Placebo
4 Completed Efficacy and Safety of Imatinib in Scleroderma
Conditions: Scleroderma, Localized;   Scleroderma, Systemic
Intervention: Drug: imatinib mesylate
5 Completed A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
Conditions: Scleroderma, Diffuse;   Scleroderma, Systemic
Intervention: Drug: Abatacept
6 Completed
Has Results
Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement
Condition: Scleroderma, Systemic
Intervention: Drug: Study subjects receive standard mycophenolate dosing.
7 Completed Psychological Treatments for Scleroderma
Conditions: Pain;   Depression;   Scleroderma;   Systemic Sclerosis
Interventions: Behavioral: Cognitive behavioral therapy;   Behavioral: Disease/health education;   Behavioral: Self-help cognitive behavioral intervention facilitated by a psychologist
8 Completed Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine
Conditions: Systemic Sclerosis;   Scleroderma
Interventions: Drug: treprostinil diethanolamine;   Drug: placebo
9 Completed Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Scleroderma Patients
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Bosentan
10 Recruiting Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Conditions: Systemic Sclerosis;   Scleroderma;   Pulmonary Hypertension;   Pulmonary Arterial Hypertension
Intervention:
11 Terminated Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients
Conditions: Scleroderma;   Systemic Sclerosis
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Thymoglobulin;   Procedure: Leukapheresis;   Procedure: Self bone marrow transplant
12 Recruiting IVIG Treatment in Systemic Sclerosis
Conditions: Systemic Sclerosis;   Diffuse Scleroderma
Intervention: Biological: Privigen
13 Recruiting Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis
Conditions: Systemic Scleroderma;   Severe Systemic Sclerosis
Interventions: Drug: fludarabine phosphate;   Drug: Mycophenolic Acid;   Drug: tacrolimus;   Radiation: total-body irradiation;   Procedure: bone marrow transplantation;   Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Procedure: biopsy;   Drug: cyclophosphamide
14 Not yet recruiting Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease
Conditions: Systemic Sclerosis;   Scleroderma;   Interstitial Lung Disease;   Lung Fibrosis
Interventions: Drug: Cyclophosphamide;   Drug: Placebo
15 Completed Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Patients With Systemic Sclerosis
Condition: Systemic Sclerosis, Scleroderma
Intervention: Drug: STI571
16 Recruiting Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository
Conditions: Scleroderma, Localized;   Morphea;   Frontal Linear Scleroderma en Coup de Sabre;   Scleroderma, Circumscribed;   Scleroderma, Linear
Intervention: Other: Morphea
17 Unknown  Scleroderma Registry
Conditions: Systemic Sclerosis;   Scleroderma
Intervention:
18 Completed Scleroderma Lung Study
Conditions: Lung Diseases;   Pulmonary Fibrosis;   Systemic Scleroderma;   Scleroderma, Systemic
Interventions: Drug: cyclophosphamide;   Drug: azathioprine
19 Unknown  Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Ambrisentan with an anti-fibrotic agent to assess benefit on skin.
20 Completed Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years